Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review

Approximately 50–60% of all patients with amyotrophic lateral sclerosis (ALS) will develop a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to one or more deficits of neuropsychological, speech or language function which are collectively known as the frontotemporal sp...

Full description

Bibliographic Details
Main Authors: Alexander J. Moszczynski, Matthew A. Hintermayer, Michael J. Strong
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-04-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fnins.2018.00259/full
id doaj-5326d8dc022b4651a5d2e2ddd9f1b972
record_format Article
spelling doaj-5326d8dc022b4651a5d2e2ddd9f1b9722020-11-25T00:20:39ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2018-04-011210.3389/fnins.2018.00259351140Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A ReviewAlexander J. Moszczynski0Matthew A. Hintermayer1Michael J. Strong2Michael J. Strong3Molecular Medicine Research Group, Schulich School of Medicine & Dentistry, Robarts Research Institute, Western University, London, ON, CanadaMolecular Medicine Research Group, Schulich School of Medicine & Dentistry, Robarts Research Institute, Western University, London, ON, CanadaMolecular Medicine Research Group, Schulich School of Medicine & Dentistry, Robarts Research Institute, Western University, London, ON, CanadaDepartment of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, Western University, London, ON, CanadaApproximately 50–60% of all patients with amyotrophic lateral sclerosis (ALS) will develop a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to one or more deficits of neuropsychological, speech or language function which are collectively known as the frontotemporal spectrum disorders of ALS (ALS-FTSD). While the neuropathology underlying these disorders is most consistent with a widespread alteration in the metabolism of transactive response DNA-binding protein 43 (TDP-43), in both ALS with cognitive impairment (ALSci) and ALS with FTD (ALS-FTD; also known as MND-FTD) there is evidence for alterations in the metabolism of the microtubule associated protein tau. This alteration in tau metabolism is characterized by pathological phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with activation of GSK3β (pTyr216GSK3β), phosphorylation of Thr231tau, and the formation of cytoplasmic inclusions with increased rates of cell death. This putative pathway of pThr175 induction of pThr231 and the formation of pathogenic tau inclusions has been recently shown to span a broad range of tauopathies, including chronic traumatic encephalopathy (CTE) and CTE in association with ALS (CTE-ALS). This pathway can be experimentally triggered through a moderate traumatic brain injury, suggesting that it is a primary neuropathological event and not secondary to a more widespread neuronal dysfunction. In this review, we discuss the neuropathological underpinnings of the postulate that ALS is associated with a tauopathy which manifests as a FTSD, and examine possible mechanisms by which phosphorylation at Thr175tau is induced. We hypothesize that this might lead to an unfolding of the hairpin structure of tau, activation of GSK3β and pathological tau fibril formation through the induction of cis-Thr231 tau conformers. A potential role of TDP-43 acting synergistically with pathological tau metabolism is proposed.http://journal.frontiersin.org/article/10.3389/fnins.2018.00259/fullamyotrophic lateral sclerosischronic traumatic encephalopathyfrontotemporal dementiaTDP-43microtubule associated tau protein
collection DOAJ
language English
format Article
sources DOAJ
author Alexander J. Moszczynski
Matthew A. Hintermayer
Michael J. Strong
Michael J. Strong
spellingShingle Alexander J. Moszczynski
Matthew A. Hintermayer
Michael J. Strong
Michael J. Strong
Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
Frontiers in Neuroscience
amyotrophic lateral sclerosis
chronic traumatic encephalopathy
frontotemporal dementia
TDP-43
microtubule associated tau protein
author_facet Alexander J. Moszczynski
Matthew A. Hintermayer
Michael J. Strong
Michael J. Strong
author_sort Alexander J. Moszczynski
title Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
title_short Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
title_full Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
title_fullStr Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
title_full_unstemmed Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis—Frontotemporal Spectrum Disorder (ALS-FTSD). A Review
title_sort phosphorylation of threonine 175 tau in the induction of tau pathology in amyotrophic lateral sclerosis—frontotemporal spectrum disorder (als-ftsd). a review
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2018-04-01
description Approximately 50–60% of all patients with amyotrophic lateral sclerosis (ALS) will develop a deficit of frontotemporal function, ranging from frontotemporal dementia (FTD) to one or more deficits of neuropsychological, speech or language function which are collectively known as the frontotemporal spectrum disorders of ALS (ALS-FTSD). While the neuropathology underlying these disorders is most consistent with a widespread alteration in the metabolism of transactive response DNA-binding protein 43 (TDP-43), in both ALS with cognitive impairment (ALSci) and ALS with FTD (ALS-FTD; also known as MND-FTD) there is evidence for alterations in the metabolism of the microtubule associated protein tau. This alteration in tau metabolism is characterized by pathological phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with activation of GSK3β (pTyr216GSK3β), phosphorylation of Thr231tau, and the formation of cytoplasmic inclusions with increased rates of cell death. This putative pathway of pThr175 induction of pThr231 and the formation of pathogenic tau inclusions has been recently shown to span a broad range of tauopathies, including chronic traumatic encephalopathy (CTE) and CTE in association with ALS (CTE-ALS). This pathway can be experimentally triggered through a moderate traumatic brain injury, suggesting that it is a primary neuropathological event and not secondary to a more widespread neuronal dysfunction. In this review, we discuss the neuropathological underpinnings of the postulate that ALS is associated with a tauopathy which manifests as a FTSD, and examine possible mechanisms by which phosphorylation at Thr175tau is induced. We hypothesize that this might lead to an unfolding of the hairpin structure of tau, activation of GSK3β and pathological tau fibril formation through the induction of cis-Thr231 tau conformers. A potential role of TDP-43 acting synergistically with pathological tau metabolism is proposed.
topic amyotrophic lateral sclerosis
chronic traumatic encephalopathy
frontotemporal dementia
TDP-43
microtubule associated tau protein
url http://journal.frontiersin.org/article/10.3389/fnins.2018.00259/full
work_keys_str_mv AT alexanderjmoszczynski phosphorylationofthreonine175tauintheinductionoftaupathologyinamyotrophiclateralsclerosisfrontotemporalspectrumdisorderalsftsdareview
AT matthewahintermayer phosphorylationofthreonine175tauintheinductionoftaupathologyinamyotrophiclateralsclerosisfrontotemporalspectrumdisorderalsftsdareview
AT michaeljstrong phosphorylationofthreonine175tauintheinductionoftaupathologyinamyotrophiclateralsclerosisfrontotemporalspectrumdisorderalsftsdareview
AT michaeljstrong phosphorylationofthreonine175tauintheinductionoftaupathologyinamyotrophiclateralsclerosisfrontotemporalspectrumdisorderalsftsdareview
_version_ 1725366043820425216